Who are Miglustat (Zavesca)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Eliglustat GZ385660, Cerdelga, Zavesca.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/miglustat-zavesca.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Miglustat (Zavesca) — Competitive Intelligence Brief

Miglustat (Zavesca) (Miglustat (Zavesca)) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Glucosylceramide synthase inhibitor. Area: Rare genetic/lysosomal storage diseases.

marketed Glucosylceramide synthase inhibitor Glucosylceramide synthase Rare genetic/lysosomal storage diseases Small molecule Live · refreshed every 30 min

Target snapshot

Miglustat (Zavesca) (Miglustat (Zavesca)) — University of Washington. Miglustat inhibits glucosylceramide synthase, reducing the accumulation of glucosylceramide and related glycosphingolipids in cells.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Miglustat (Zavesca) TARGET	Miglustat (Zavesca)	University of Washington	marketed	Glucosylceramide synthase inhibitor	Glucosylceramide synthase
Eliglustat GZ385660	Eliglustat GZ385660	Sanofi	phase 3	Glucosylceramide synthase inhibitor	Glucosylceramide synthase (GCS)
Cerdelga	ELIGLUSTAT	Sanofi	marketed	Glucosylceramide Synthase Inhibitor [EPC]	Ceramide glucosyltransferase	2014-01-01
Zavesca	MIGLUSTAT	AstraZeneca	marketed	Glucosylceramide Synthase Inhibitor [EPC]	Lysosomal alpha-glucosidase	2003-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2033-03-07 — Zavesca · 12419937 · Method of Use · US
2033-03-07 — Zavesca · 11278599 · Method of Use · US
2033-03-07 — Zavesca · 10512677 · Method of Use · US
2035-09-30 — Zavesca · 10961522 · Method of Use · US
2035-09-30 — Zavesca · 10208299 · Compound · US
2035-09-30 — Zavesca · 11753632 · Method of Use · US
2036-12-29 — Zavesca · 11278601 · Formulation · US
2036-12-29 — Zavesca · 12414985 · Method of Use · US
2037-08-12 — Zavesca · 10857212 · Method of Use · US
2038-09-16 — Zavesca · 12246062 · Method of Use · US

Sponsor landscape (Glucosylceramide synthase inhibitor class)

Sanofi · 1 drug in this class
University of Washington · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Miglustat (Zavesca) — Competitive Intelligence Brief. https://druglandscape.com/ci/miglustat-zavesca. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab